These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 11291832)

  • 41. Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents.
    Fukushima M; Iizuka K; Jin C; Zhang C; Hong M; Eshima K
    Drug Des Devel Ther; 2017; 11():1693-1705. PubMed ID: 28652707
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil.
    Hoff PM; Lassere Y; Pazdur R
    Drugs; 1999; 58 Suppl 3():77-83. PubMed ID: 10711845
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
    Adjei AA; Reid JM; Diasio RB; Sloan JA; Smith DA; Rubin J; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Atherton P; Ames MM; Erlichman C
    J Clin Oncol; 2002 Mar; 20(6):1683-91. PubMed ID: 11896120
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines: a novel class of oral antineoplastic agents.
    Hoff PM; Pazdur R
    Semin Oncol; 1999 Dec; 26(6 Suppl 18):52-6. PubMed ID: 10892578
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacology of fluorinated pyrimidines: eniluracil.
    Baker SD
    Invest New Drugs; 2000 Nov; 18(4):373-81. PubMed ID: 11081573
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Oral fluoropyrimidines in oncology].
    González Barón M
    An R Acad Nac Med (Madr); 1998; 115(3):721-45; discussion 745-6. PubMed ID: 10208021
    [No Abstract]   [Full Text] [Related]  

  • 47. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.
    Baker SD; Khor SP; Adjei AA; Doucette M; Spector T; Donehower RC; Grochow LB; Sartorius SE; Noe DA; Hohneker JA; Rowinsky EK
    J Clin Oncol; 1996 Dec; 14(12):3085-96. PubMed ID: 8955653
    [TBL] [Abstract][Full Text] [Related]  

  • 48. DPD functional tests in plasma, fresh saliva and dried saliva samples as predictors of 5-fluorouracil exposure and occurrence of drug-related severe toxicity.
    Neto OV; Raymundo S; Franzoi MA; do Carmo Artmann A; Tegner M; Müller VV; Hahn RZ; Alves GV; Schwartsmann G; Linden R; Antunes MV
    Clin Biochem; 2018 Jun; 56():18-25. PubMed ID: 29625079
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.
    Takechi T; Okabe H; Ikeda K; Fujioka A; Nakagawa F; Ohshimo H; Kitazato K; Fukushima M
    Oncol Rep; 2005 Jul; 14(1):33-9. PubMed ID: 15944764
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 5-fluorouracil: a pharmacological paradigm in the use of cytotoxics.
    Thomas DM; Zalcberg JR
    Clin Exp Pharmacol Physiol; 1998 Nov; 25(11):887-95. PubMed ID: 9807659
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Xeloda in colorectal cancer.
    Cassidy J
    Int J Clin Pract; 2001 Jun; 55(5):326-8. PubMed ID: 11452682
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The clinical pharmacology of the oral fluoropyrimidines.
    Takimoto CH
    Curr Probl Cancer; 2001; 25(3):134-213. PubMed ID: 11408845
    [No Abstract]   [Full Text] [Related]  

  • 53. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.
    Caudle KE; Thorn CF; Klein TE; Swen JJ; McLeod HL; Diasio RB; Schwab M
    Clin Pharmacol Ther; 2013 Dec; 94(6):640-5. PubMed ID: 23988873
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Fluorinated pyrimidines in oral treatment of advanced colorectal cancer].
    Todnem K; Harboe K; Zotova L; Lind A; Ogreid D
    Tidsskr Nor Laegeforen; 2000 Sep; 120(23):2781-5. PubMed ID: 11107924
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Pharmacokinetics of S-1].
    Hirata K; Horikoshi N; Tominaga K; Sohma K; Yamaguchi K; Okazaki M; Furuhata T; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Yamamitsu S; Shirasaka T
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():27-35. PubMed ID: 16897969
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The evolution of fluoropyrimidine therapy: from intravenous to oral.
    Hoff PM; Cassidy J; Schmoll HJ
    Oncologist; 2001; 6 Suppl 4():3-11. PubMed ID: 11585968
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer.
    Schmoll HJ
    Anticancer Drugs; 2003 Oct; 14(9):695-702. PubMed ID: 14551502
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer.
    Cunningham D; James RD
    Eur J Cancer; 2001 May; 37(7):826-34. PubMed ID: 11313169
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Capecitabine in carcinoma of the pancreas.
    Smith DB; Neoptolemos JP
    Expert Opin Pharmacother; 2006 Aug; 7(12):1633-9. PubMed ID: 16872266
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors.
    Peters GJ; Noordhuis P; Van Groeningen CJ; Giaccone G; Holwerda U; Voorn D; Schrijvers A; Schornagel JH; Beijnen JH; Fumoleau P; Schellens JH
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4072-6. PubMed ID: 15217941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.